Weekly Investment Analysts’ Ratings Updates for WAVE Life Sciences (WVE)

WAVE Life Sciences (NASDAQ: WVE) has recently received a number of price target changes and ratings updates:

• 11/12/2026 – WAVE Life Sciences had its price target lowered by Citigroup from $19.00 to $15.00. They now have a “buy” rating on the stock.
• 11/9/2026 – WAVE Life Sciences had its “buy” rating reaffirmed by B. Riley Financial. They now have a $18.00 price target on the stock.
• 10/31/2026 – WAVE Life Sciences was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 10/28/2026 – WAVE Life Sciences is now covered by HC Wainwright. They set a “strong-buy” rating on the stock.
• 10/27/2026 – WAVE Life Sciences was given a new $10.00 price target by Leerink Partners.
• 10/16/2026 – WAVE Life Sciences is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – WAVE Life Sciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – WAVE Life Sciences is now covered by UBS Group. They set a “buy” rating and a $11.00 price target on the stock.
• 10/14/2026 – WAVE Life Sciences was upgraded by UBS Group to “strong-buy”.
• 10/2/2026 – WAVE Life Sciences was given a new $13.00 price target by Wedbush.
• 10/2/2026 – WAVE Life Sciences had its “buy” rating reaffirmed by HC Wainwright.
• 10/1/2026 – WAVE Life Sciences is now covered by Ladenburg Thalmann & Co. Inc.. They set a “buy” rating and a $10.00 price target on the stock.
• 9/23/2026 – WAVE Life Sciences is now covered by JPMorgan Chase & Co.. They set a “neutral” rating on the stock.

WAVE Life Sciences Stock Down 1.6%

WAVE Life Sciences stock traded down $0.06 during midday trading on Thursday, hitting $3.37. The company’s stock had a trading volume of 557,596 shares, compared to its average volume of 3,674,353. WAVE Life Sciences Ltd. has a 12 month low of $3.04 and a 12 month high of $21.73. The company has a market capitalization of $663.68 million, a PE ratio of -3.14 and a beta of -1.40. The stock’s 50-day moving average price is $3.80 and its 200-day moving average price is $7.07.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Tuesday, October 27th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. The company had revenue of $13.16 million during the quarter, compared to analyst estimates of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative return on equity of 44.66%. As a group, equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.08 EPS for the current year.

WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.